公开(公告)号：US11078191B2

公开(公告)日：2021-08-03

申请号：US16484183

申请日：2018-02-08

申请人： Novartis AG ,  Palobiofarma S.L.

发明人： Sanela Bilic ,  Juan Alberto Camacho Gomez ,  John Scott Cameron ,  Julio Cesar Castro-Palomino Laria ,  Danny Roland Howard, Jr.

IPC分类号： C07D403/14 ,  C07K16/28 ,  A61K31/506 ,  A61P35/00

摘要： This invention relates to an active metabolite of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimindin-4-amine that modulates the activity of adenosine A2a receptor. In particular, the present invention relates to pharmaceutical compositions comprising 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)-pyrimidin-2-yl)-1H-pyrazol-4-ol, as well as processes for its preparation and its use in the treatment of cancer alone of in combination with one or more immunotherapeutic agents.

公开(公告)号：US10561653B2

公开(公告)日：2020-02-18

申请号：US15751140

申请日：2016-08-10

申请人： NOVARTIS AG ,  PALOBIOFARMA, S.L.

发明人： Sanela Bilic ,  Juan Alberto Camacho Gomez ,  John Scott Cameron ,  Julio Cesar Castro-Palomino Laria ,  Danny Roland Howard, Jr.

IPC分类号： A61K39/395 ,  A61K31/506 ,  A61P35/00 ,  A61K39/00

摘要： The present invention relates to 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine, its pharmaceutically acceptable salts and co-crystals thereof and to pharmaceutical compositions comprising said compounds for use in the treatment of cancer.

公开(公告)号：US20190151365A1

公开(公告)日：2019-05-23

申请号：US16321322

申请日：2017-07-28

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Oezlem Anak ,  Sanela Bilic ,  Jennifer Brogdon ,  John Scott Cameron ,  William Chou ,  Stephan Grupp ,  Danny Roland Howard, Jr. ,  Randi Isaacs ,  Carl H. June ,  Simon Lacey ,  Shannon Maude ,  Jan J. Melenhorst ,  Stephen Shuster ,  Alfonso Quintas-Cardama

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  A61P35/00 ,  G01N33/574

摘要： Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of an antigen, e.g., CD 19, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., CD19, in combination with a PD-1 inhibitor.

公开(公告)号：US20200261573A1

公开(公告)日：2020-08-20

申请号：US16061470

申请日：2016-12-19

申请人： Novartis AG

发明人： Sanela Bilic ,  Danny Roland Howard JR ,  John Scott Cameron

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61P35/04 ,  A61K31/53

摘要： The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.

公开(公告)号：US20180371093A1

公开(公告)日：2018-12-27

申请号：US16062427

申请日：2016-12-16

申请人： Sanela Bilic ,  Danny Roland Howard, JR. ,  John Scott Cameron ,  Glenn Dranoff ,  Novartis AG

发明人： Sanela Bilic ,  Danny Roland Howard, JR. ,  John Scott Cameron ,  Glenn Dranoff

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K31/337

摘要： Antibody molecules that specifically bind to PD-1 are disclosed. The antibody molecules can be used to treat or prevent cancerous or infectious conditions and disorders.